Pre-made Glembatumumab biosimilar ( Whole mAb ADC, anti-GPNMB therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-246
Anti-GPNMB therapeutic antibody (Pre-made Glembatumumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-GPNMB therapeutic antibody (Pre-made Glembatumumab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA)|
|Conditions Discontinued||Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma|